Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
Holding COR?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
$3.49Last Year’s EPS
$3.28Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -2.47%
|Next Earnings Date:Jan 30, 2025
Earnings Call Sentiment|Positive
Cencora showed strong financial performance with significant EPS and revenue growth, strategic acquisition to enhance service capabilities, and shareholder returns through increased dividends and share repurchases. However, challenges remain with goodwill impairment in PharmaLex and decreased margin pressures.Company Guidance
During the Cencora Q4 2024 earnings call, the company provided guidance for fiscal 2025, projecting adjusted diluted EPS in the range of $14.80 to $15.10, representing an 8% to 10% growth. Revenue growth is expected to be between 7% and 9%, while operating income is anticipated to grow between 5% and 6.5%. The effective tax rate is projected to be approximately 21%, with a full-year average share count of roughly 196 million shares. The company plans capital expenditures of around $600 million and expects adjusted free cash flow to be between $2 billion and $3 billion. Notably, the guidance does not yet factor in the impact of the recently announced acquisition of Retina Consultants of America.Strong EPS Growth
Cencora reported adjusted diluted EPS of $3.34 in Q4, representing a 17% increase compared to the prior year quarter, and full fiscal year 2024 adjusted diluted EPS of $13.76, a 15% increase compared to the prior fiscal year.
Revenue Growth
Consolidated revenue was $79.1 billion, up 15%, driven by growth in both reportable segments, particularly strong script utilization and growth in European and Canadian businesses.
RCA Acquisition
Cencora announced the acquisition of Retina Consultants of America, which broadens community provider relationships in a high-growth segment and supports pharmaceutical innovation.
Opportunistic Share Repurchases
Cencora returned $1.9 billion to shareholders through dividends and share repurchases, including $1.5 billion in opportunistic share repurchases.
Dividend Increase
The Board of Directors approved an 8% increase to the quarterly dividend, marking the 20th consecutive annual dividend increase.
---
COR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
COR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $233.46 | $244.82 | +4.87% |
| Jul 31, 2024 | $230.01 | $236.83 | +2.97% |
| May 01, 2024 | $237.46 | $227.67 | -4.12% |
| Jan 31, 2024 | $218.59 | $230.63 | +5.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cencora (COR) report earnings?
Cencora (COR) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Cencora (COR) earnings time?
Cencora (COR) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COR EPS forecast?
COR EPS forecast for the fiscal quarter 2025 (Q1) is $3.49.
---